Parkinsonism & related disorders · 2026
Preserved cardiovascular autonomic function predicts the response to initial MAO-B inhibitor treatment in Parkinson's disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ito Naohito, Ozawa Junnosuke, Kataoka Kazuyuki, Matsuoka Kaoru, Nakanishi Tatsuya, Wada Takahide, Ishida Atsushi, Kanemoto Mizuki, Oguchi Tatsunori, Tsuji Mayumi, Kiuchi Yuji, Murakami Hidetomo
Аннотация
INTRODUCTION: Monoamine oxidase-B (MAO-B) inhibitors enhance endogenous dopaminergic activity and are well tolerated in initial therapy for Parkinson's disease (PD). However, clinical responsiveness differs and reliable predictors of treatment response are unavailable.
METHODS: The association between baseline characteristics and motor responsiveness was examined in drug-naïve patients with PD initiated on MAO-B inhibitor monotherapy in comparison to levodopa treatment. Baseline assessments included motor severity, cardiovascular autonomic function (evaluated using the head-up tilt test), 123I-metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy and neuropsychological measures, including assessments of executive function, mood, and motivational states associated with endogenous dopamine levels. The motor outcome was defined as the percentage change in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score after 10 w.
RESULTS: Of 21 patients treated with MAO-B inhibitors, smaller orthostatic blood pressure declines at 3 min were strongly associated with greater motor improvement (ΔSBP: r = -0.520, p = 0.019; ΔDBP: r = -0.510, p = 0.022). Higher cardiac 123I-MIBG uptake predicted greater response (early: r = 0.518, p = 0.016; delayed: r = 0.516, p = 0.017), even after multivariate adjustment. In 18 patients treated with levodopa, treatment response was associated with cardiac 123I-MIBG uptake in univariate analyses but not orthostatic blood pressure changes; however, this association did not remain significant after multivariate adjustment.
CONCLUSION: Preserved cardiovascular autonomic function, particularly mild orthostatic hypotension, emerged as a predictor of a favorable response to MAO-B inhibitors in early PD, potentially aiding the individualization of initial dopaminergic therapy.
METHODS: The association between baseline characteristics and motor responsiveness was examined in drug-naïve patients with PD initiated on MAO-B inhibitor monotherapy in comparison to levodopa treatment. Baseline assessments included motor severity, cardiovascular autonomic function (evaluated using the head-up tilt test), 123I-metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy and neuropsychological measures, including assessments of executive function, mood, and motivational states associated with endogenous dopamine levels. The motor outcome was defined as the percentage change in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score after 10 w.
RESULTS: Of 21 patients treated with MAO-B inhibitors, smaller orthostatic blood pressure declines at 3 min were strongly associated with greater motor improvement (ΔSBP: r = -0.520, p = 0.019; ΔDBP: r = -0.510, p = 0.022). Higher cardiac 123I-MIBG uptake predicted greater response (early: r = 0.518, p = 0.016; delayed: r = 0.516, p = 0.017), even after multivariate adjustment. In 18 patients treated with levodopa, treatment response was associated with cardiac 123I-MIBG uptake in univariate analyses but not orthostatic blood pressure changes; however, this association did not remain significant after multivariate adjustment.
CONCLUSION: Preserved cardiovascular autonomic function, particularly mild orthostatic hypotension, emerged as a predictor of a favorable response to MAO-B inhibitors in early PD, potentially aiding the individualization of initial dopaminergic therapy.